Notably, the rational structural modifications of AChE inhibitors were still the primary route to the discovery of novel One-molecule-multi-target anti-AD drugs at this stage (Rossi et al., 2021; Sang et al., 2022; Turgutalp et al., 2022). The gene discussed is ACHE; the disease is Alzheimer disease.